Last reviewed · How we verify
Taflotan-S
Taflotan-S is a Small molecule drug developed by Taejoon Pharmaceutical Co., Ltd.. It is currently FDA-approved.
Tafluprost, also known as S 3304, is a small molecule used in the treatment of ocular conditions such as ocular hypertension, open-angle glaucoma, and glaucoma. It is administered as an eye drop, with various formulations including Tafluprost 0.0015% and Xalost S, and has been compared to other interventions like Xalatan in clinical trials.
At a glance
| Generic name | Taflotan-S |
|---|---|
| Sponsor | Taejoon Pharmaceutical Co., Ltd. |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Evaluating the Efficacy and Safety of Xalost S in Glaucoma Patients. (PHASE4)
- Efficacy and Tolerability of Preservative-free 0.0015% Tafluprost in Glaucoma Patients (PHASE4)
- The Effects of Preservative-free Prostaglandin Eye Drops in Sign and Symptoms on the Eyes of Patients With Glaucoma (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Taflotan-S CI brief — competitive landscape report
- Taflotan-S updates RSS · CI watch RSS
- Taejoon Pharmaceutical Co., Ltd. portfolio CI
Frequently asked questions about Taflotan-S
What is Taflotan-S?
Who makes Taflotan-S?
What development phase is Taflotan-S in?
Related
- Manufacturer: Taejoon Pharmaceutical Co., Ltd. — full pipeline
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing